AEON Biopharma is the only company dedicated exclusively to the use of botulinum toxins for therapeutic-only indications. With ABP-450 (prabotulinumtoxinA), we are advancing a well-established product into fast growing markets for both expanded and novel indications utilizing a differentiated business model intended to deliver enhanced pharmacoeconomics to payers and providers.
Innovating the $3.0B therapeutic neurotoxin market.
Same 900 kDa neurotoxin complex approved for cosmetic indications
Differentiated economics to payors and physicians
Managements team with significant neurotoxin and biopharma experience
Learn More